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Abstract 
 
Background: To study the incidence of anaemia  during 
antiviral treatment and the effectiveness of erythropoietin 
to correct it. 
 
Methods: This prospective, observational study 
included 208 subjects with PCR positive for HCV RNA 
who presented in Shafi Clinic Rawalpindi. Duration of the 
study was 2 years.  All patients were given antiviral 
treatment including interferon and ribavirin. Baseline Hb 
and all other laboratory parameters were checked. Any 
drop in Hb after initiation of therapy was noted. Patients 
who had Hb < 10g/dl were given inj erythropoietin for 
correction of anaemia.  
 
Results: Of the 208 patients, 99 were males (48%) and 107 
(52%) females. 172 patients (82.7%) were given 
conventional interferon  whereas 38 patients (17.3%) were 
given PEG-IFN along with ribavirin. Anaemia ie Hb less 
than 10g/dl developed in 38 cases (18.5%). Hb <8g/dl 
developed in 7 cases (3.4%). Out of these 38 cases; 30 
patients had received conventional interferon whereas 8 
patients had received  PEG-IFN. Mean drop in Hb was 
from 11.5 to 6.0 g/dl mostly seen between 2-4 weeks. All 
patients were given inj Epo . All had significant increase 
in Hb upto 11.5 +/- 0.2 g/dl over 6-8 weeks. No patient 
required treatment discontinuation because of anaemia. 
 
Conclusion:  It is concluded that anaemia is a common 
adverse effect of antiviral treatment. Recombinant human 
erythropoietin alpha  is very effective to counter this 
problem without requiring blood transfusion or dose 
reduction. It allows adherence and maintenance of critical 
dose level producing optimal HCV treatment. 
 
Introduction 
 
HCV is currently the most common cause of 
cirrhosis and end-stage liver disease. It is responsible 
for more than 50% of liver transplants being 
performed1. HCV infects almost 3% of world’s 
population i.e., 170 million people 2. About 10-20% of 
chronically infected persons progress to cirrhosis over 
an average of 20 years 3, 4. Prevalence of HCV infection 
is increasing worldwide. Viral eradication is the only 
way to prevent disease progression. A recent NIH 
consensus guideline recommended treatment with 
pegylated interferon and ribavirin for patients with 
HCV-RNA viral loads higher than 50 copies per ml; a 
liver biopsy with portal or bridging fibrosis and at 
least moderate inflammation and necrosis 5. 
Recommended doses of drugs for antiviral treatment 
are:- 6, 7. 
Conventional IFN: 3 MIU  S/C thrice a week. 
PEG-IFN α 2b (Pegintron): 1.5 mcg per kg S/C once 
weekly. 
PEG-IFN α 2a (Pegasys): 180 mcg S/C once weekly. 
Ribavirin capsule according to body weight: 
<55 kg  400 mg 1+1 daily 
55-75 kg  500 mg 1+ 1 daily 
>75 kg  400 mg 1+1+1 daily 
Anaemia , leucopenia and thrombocytopenia  
are among the numerous  side effects of currently 
available  antiviral treatment 8, 9.  Ribavirin and 
interferon both cause anaemia. Ribavirin causes 
anaemia by extravascular hemolysis and suppression 
of erythropoiesis by downregulation of Epo receptors 
10,11. Interferon causes anaemia by suppression of 
hematopoeitic progenitor cell proliferation, activation 
of programmed cell death in erythroid progenitor 
cells12 and provocation of immune hemolysis  and 
impairment of renal function If Hb level falls below 
10g/ dl , ribavirin dose should be reduced by 200 to 
400 mg/ day. If it drops to below 8.5 g/dl; ribavirin 
should be discontinued. 6,7 
Anaemia tends to occur less frequently with 
PEG-IFN than with non–pegylated IFN.13. When 
combination therapy is used, Hb less than 11g/dl 
occurs in  25 to 30% of patients 14. Anaemia is more 
pronounced with combination therapy than with IFN- 
alpha monotherapy. 13  
Most important factors in successful 
eradication of HCV are adherence to therapy and dose 
maintenance.13 Anaemia accounts for about 36% of 
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Recombinant human erythropoietin therapy  
represents an alternative to ribavirin dose reduction or 
discontinuation. We conducted a study to note the 
incidence of anaemia during combination therapy and 
to determine the effect of erythropoietin on correction 
of anaemia. 
 
Patients and Methods 
 
It was a prospective observational study. 
Patients with PCR + ve for HCV- RNA  presenting in 
Shafi Clinic Rawalpindi with age between 18 to 65 
years were included in the study. Duration of study 
was 2 years ie from July 2005 to July 2007. Sample size 
was 208 patients. A simple convenient sampling 
technique was used.   
Patients with any major comorbidity e.g., IHD 
or CRF, those with HCC, those with CTP- class C or 
any contraindication to  INF or ribavirin were not 
included. Similarly pregnant ladies and those with 
baseline TLC < 3000/cmm and baseline Hb < 8g/dl 
were excluded from the study.  
Patients who were lost to final follow- up were 
also not included. 
Complete baseline tests including CBC, LFTs, 
RFTs, BSR, TFTs and USG abdomen were done before 
enrollment. Serotyping of HCV was not done in all 
patients because of affordability problems. Also the 
common serotypes in our region are 2 and 3 mostly. 
These serotypes are very much responsive to 
conventional interferon. Standard combination 
therapy was given to all i.e., interferon and ribavirin. 
Most of the patients were given conventional 
interferon because of its low cost.  
Follow up was  done initially 2 weekly for 2-3 
months and then monthly till end of treatment. Blood 
CP and ALT were  repeated at each follow up to look 
for any complication.  
In patients who developed anaemia, Inj. 
Erythropoietin was administered according to severity 
of anaemia i.e., Hb  < 8 g/dl  inj Epo 4000 units  SC 
twice a week. Hb > 8 g/dl but < 10 g/dl Inj Epo 
4000units  SC once weekly. Response to treatment was 
noted and dose titration done accordingly. Treatment 
stopped at the end of six months by repeating PCR. 
Results 
 
Total patients were 208 of which males were 
99 (48%) and females 109 (52%). Age ranged from 18 to 
65 years with maximum patients aged between 30 to 
50 years (Fig.1)  
Patients who received conventional IFN were 
172 (82.7%) and those who received pegylated IFN 
were 36 (17.3%). Serotyping was done in 133 cases 
only. It revealed 100 cases of Serotype 3, 32 cases of 
untypable serotype and 1 case of Serotype 2b. 
 
Fig.1: Age of patients  
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Anaemia ie Hb less than 10 g/ dl occurred in 
38 cases out of 208 (18.5%). Hb drop to less than 8 g/dl 
was seen in 7 cases (3.4 %). Out of these 38 cases, 30 
patients were on conventional IFN (80%) and 8 
patients were on PEG-IFN (20%), both in combination 
with ribavirin. 
Hb  <  8 g/dl was seen in 7 cases, all on 
conventional IFN. Hb > 8 but < 10g/dl was seen in 31 
cases including 8 using PEG-IFN (Fig. 2). 
 
Fig.2: Severity of Anaemia  
 
 
 
 
 
 
 
 
 
 
 
 
 
Thus anaemia observed in 2 Groups was as follows: 
Conventional IFN   =    30 / 172 x  100 =   17.4 % 
PEG-IFN                 =    8 / 36     x  100 =   22.2% 
Mean drop in Hb was from 11.5 to 6.0g/dl. 
Maximum decline was seen about 2-4 weeks after 
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antiviral treatment. (Fig.3). All these patients were 
given Inj Epo according to dose mentioned above. All 
the patients had a significant increase in Hb over a 
period of 6-8 weeks. Hb levels rose back to 11.5 +/- 
0.2. No patient required blood transfusion or 
discontinuation of therapy. All patients were able to 
complete desired dose and duration of therapy. 
 
Fig. 3: Change in Haemoglobin levels  
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
 Anaemia, leucopenia and thrombocytopenia 
are common adverse effects of antiviral treatment. 
These side effects compromise treatment adherence 
and dose maintenance. Response rate is lower for 
patients who do not complete their treatment course 
or who receive < 80% of the intended dose for < 80% 
of the intended time  16-19. 
In clinical trials, significant .anaemia (Hb < 10 
g/ dl) has been observed in 9- 13% of patients. 
Moderate anaemia (Hb < 11 g/dl) may be seen in 30% 
of cases6. Recombinant human Epoeitin alpha allows 
correction of anaemia without treatment 
discontinuation or blood transfusion.20-22. It acts like 
endogenous Epo.  
Though there are no official guidelines for its 
use in HCV treatment associated anaemia but studies 
have proven it very beneficial.13. In comparison with 
non-pharmacological treatment  ie dose reduction or 
blood transfusion, Epo improves Hb level more 
effectively. Percentage of patients who were able to 
maintain > 10.6 mg / kg/ day of ribavirin dose was 
also significantly greater in Epo group.22  
 
Conclusion 
 
It is concluded that anaemia is a common 
adverse effect of antiviral treatment. Recombinant 
human erythropoietin alpha is very effective to 
counter this problem without requiring blood 
transfusion or dose reduction. It allows adherence and 
maintenance of critical dose level producing optimal 
HCV treatment. 
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